FierceBiotech

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depre

ABILIFY is the first medication approved by the FDA as add-on treatment for MDD. "The approval of this new add-on treatment option is critical for adults suffering from depression who cannot find ...
EurekAlert!

FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD

PRINCETON, NJ and TOKYO, JAPAN, November 20, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...
Hosted on MSN

9 Side Effects of Abilify to Know

Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...
FierceBiotech

PRESS RELEASE: FDA Approves Otsuka Pharmaceutical and Bristol-Myers Squibb's ABILIFY for Adolescent Patients With Schizophrenia

TOKYO and PRINCETON, N.J., Nov. 6 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY - News) announced today that the U.S. Food and Drug Administration (FDA) approved the ...